Track topics on Twitter Track topics that are important to you
Nonalcoholic steatohepataitis NASH Pipeline Analysis gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development Discovery, Preclinical Clinical. The pipeline focuses on novel pharmacologic drugs regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNAbased therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepataitis NASH drugs market. The report also provide strategic insights on some of the molecules that are yet to be launched in the next few years. Some of the key sections covered in the report are given below:
In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.
Global US prevalence rates
Hot Targets, Mechanisms Therapies
In this section, various NASH associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for NASH along with disease progression biomarkers associated with NASH Inflammatory, apoptosis, fibrosis
In market analysis section, global NASH drugs market is indicated along with the estimated Peak sales $ of leading clinical stage drugs forecasted from 20192025.
Forecasting model for NASH market
NASH market dynamics
NASH Market and estimated Peak sales of 8 clinical candidates OCAIntercept, AramcholGalmed, GRMD02Gilead, CenicrivirocTobira, SimtuzumabGilead, Remo BiphasicAvolynt, IVA 337Inventiva Pharma, GFT505Genfit
NASH related deals analysis with financials upfront, milestones and royalties
Funding scenario in NASH market
Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status nature of molecule. Pipeline analysis by developmental stage Discovery to Clinical development
Pipeline analysis by modalities
Monoclonal Antibodies pipeline analysis
RNAtherapeutics pipeline analysis
Recombinant protein pipeline analysis
Pipeline analysis by leading players Target analysis
Drug analysis based on mechanism AntiInflammatory, Antifibrotic Metabolic
Key Players Analysis
The key player's analysis section provides an indepth understanding of various companies working on Nonalcoholic steatohepatitis NASH and their Pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Global key players overview
Global key players Pipeline data Discovery, Preclinical Clinical development
Global key players deals Collaborations, Licensing, Service agreements, grants, funds
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Track and monitor developments in stem cell research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry. BioPort...
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...